Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


NDSAC Interim Recommendations regarding esomeprazole 20 mg

A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held via electronic participation from October 4-10, 2018 with the following interim recommendations made:

  • esomeprazole or its salts, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole, be granted Schedule III status
  • esomeprazole or its salts, EXCEPT when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of esomeprazole, be retained in Schedule I;

Any objections to these interim recommendations must be received by the NAPRA office by end of day November 10, 2018. Questions or comments should be directed to the Manager, Professional and Regulatory Affairs, Sarah Marshall via email at smarshall@napra.ca.

Date: